The company has completed its pivotal clinical trial for the Butterfly prostatic retraction device.

The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is racing to advance ...

An enlarged prostate is a big problem for men, no pun intended. According to Yale Medicine, about 50% of men between the ages of 51 and 60 have benign prostatic hyperplasia (BPH) or an enlarged ...

May 18 (Reuters) - American Medical Systems Holdings Inc. said it received regulatory approval for its new device to treat benign enlargement of the prostate. The urological medical device supplier ...

Less than a week after making a regulatory submission for a $1 million capital raise, prostate health company ProUroCare Medical, based in Eden Prairie, Minnesota, announced that it has secured market ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

ProUroCare Medical, Inc., of Minneapolis, Minn., has filed a de novo application with the FDA seeking marketing clearance for its prostate mechanical imaging (PMI) device (ProUroScan). This will allow ...

Charlotte, N.C.-based SonaCare Medical earned clearance from the Food and Drug Administration for a new version of its Sonablate device. Sonablate, intended for use in the focused ablation of prostate ...

The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued draft guidance Tuesday to support clinical testing of high-intensity ultrasound systems for ...

Butterfly Medical announced today that it completed its Series C funding round, bringing in $21 million to support its BPH ...